menu search

REUN / Psychedelic Sunday: Ketamine Assisted Therapy

Psychedelic Sunday: Ketamine Assisted Therapy
When will capital markets catch up to psychedelic industry? Ronan Levy, CEO and Co-Founder of Field Trip, discusses strategy behind focusing on ketamine assisted therapy. Read More
Posted: Jan 29 2023, 11:30
Author Name: Seeking Alpha
Views: 101915

REUN News  

Reunion Neuroscience sees $48.5M loss in FY23 ahead of going private

By Proactive Investors
June 30, 2023

Reunion Neuroscience sees $48.5M loss in FY23 ahead of going private

Reunion Neuroscience Inc Thursday reported a net loss of $48,492,996 for its fiscal year 2023, even as the company remains upbeat on the development o more_horizontal

Reunion Neuroscience Inc. (REUN) Q3 2023 Earnings Call Transcript

By Seeking Alpha
February 14, 2023

Reunion Neuroscience Inc. (REUN) Q3 2023 Earnings Call Transcript

Reunion Neuroscience Inc. (NASDAQ:REUN ) Q3 2023 Earnings Conference Call February 14, 2023 8:30 AM ET Company Participants Edward Smith - CFO Greg Ma more_horizontal

Psychedelic Sunday: Ketamine Assisted Therapy

By Seeking Alpha
January 29, 2023

Psychedelic Sunday: Ketamine Assisted Therapy

When will capital markets catch up to psychedelic industry? Ronan Levy, CEO and Co-Founder of Field Trip, discusses strategy behind focusing on ketami more_horizontal

Reunion Neuroscience, Inc. (REUN) Q2 2023 Earnings Call Transcript

By Seeking Alpha
November 15, 2022

Reunion Neuroscience, Inc. (REUN) Q2 2023 Earnings Call Transcript

Reunion Neuroscience, Inc. (NASDAQ:REUN ) Q2 2023 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Phil Carlson - IR, MD, KC more_horizontal


Search within

Pages Search Results: